Social Media Ideas for Daraxonrasib

Daraxonrasib shows early antitumor activity in RAS-mutant lung cancer

Daraxonrasib, Revolution Medicines tarafından geliştirilen deneysel bir oral RAS inhibitörü, ameliyat dışı NSCLC olgularının yaklaşık üçte birini oluşturan ve PD-1 ek...

Breaking News: Daraxonrasib Approved for Pancreatic Cancer

Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on...

<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]>

Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common...

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

FDA clears Revolution Medicines' targeted pancreatic cancer pill

REDWOOD CITY, California: The U.S. Food and Drug Administration has approved Revolution Medicines' targeted drug Rasonque for adults with metastatic pancreatic cancer who have rece...

FDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly Doubles Survival

The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial results suggesting the drug can substantially extend survival...

Udarrogari Ras

Udarrogari Ras – Ingredients, Preparation, Ayurvedic Properties, Indications & Dosages REFERENCE – Rastantrasaar evum Siddhpryog Sangreh/ Udar roga/ chapter 31/ ... Read more T...

Arkeshwar Ras

Arkeshwar Ras – Ingredients, Preparation, Ayurvedic Properties, Indications & Dosages Introduction Raktapitta is a significant clinical condition in Ayurveda characterized ......

A Game-Changing Drug for Pancreatic Cancer Just Got FDA Approval

In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving...

FDA approves Rasonque for advanced pancreatic cancer patients in the US

BATON ROUGE — The FDA has approved a new drug for patients with advanced pancreatic cancer, with doctors calling it a turning point in treating the disease.The once-daily...

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

FDA approves landmark pancreatic cancer drug that's shown to improve survival

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment ag...

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

In April, Revolution shares rocketed 54% after the company announced dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating Rasonque in patients with metastat...

FDA approves landmark pancreatic cancer drug thats shown to improve survival

(AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment...

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mecha...

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a mo...